<DOC>
	<DOCNO>NCT02178709</DOCNO>
	<brief_summary>The primary objective study evaluate rate pathologic complete response neoadjuvant FOLFIRINOX patient resectable pancreatic cancer use tissue collection component .</brief_summary>
	<brief_title>A Phase II Study Neoadjuvant FOLFIRINOX</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>1 . ≥ 18 year old time inform consent 2 . Able provide write informed consent HIPAA authorization 3 . ECOG performance status 0 1 4 . Patient must eligible abdominal surgery 5 . Histologically confirm adenocarcinoma pancreas document resectable standardized radiographic criterion pancreatic surgeon 6 . Patients must tumor tissue collect prior enrol trial . Up 10 patient accepted pretreatment research tissue collection tissue collection outside institution . a.If tissue outside institution , must review Indiana University Health Pathology Department biopsy perform outside institution . 7 . Women childbearing potential definition ( WOCBP ) must negative serum urine pregnancy test perform within 14 day prior initiation FOLFIRINOX . Any woman ( regardless sexual orientation , undergone tubal ligation , remain celibate choice ) classify WOCBP meet follow criterion : 1 . Has undergone hysterectomy bilateral oophorectomy ; 2 . Has naturally postmenopausal least 24 consecutive month ( i.e. , menses time precede 12 consecutive month ) . 8 . WOCBP men must agree use adequate contraception prior , study entry , duration study participation , 8 week end treatment . 9 . Patients must adequate organ function define follow laboratory value study entry : 1 . Hemoglobin ≥ 9 g/dL ( transfusion acceptable ) 2 . ANC ≥ 1.5 x 109/L 3 . Platelets ≥ 100 x 109/L 4 . Creatinine ≤ 1.5 x ULN , creatinine clearance ≥ 50 mL/min ( estimate CockcroftGault measure ) 5 . Total bilirubin ≤ 1.5 x ULN 6 . AST/ALT ≤ 3 x ULN 1 . Prior therapy pancreatic adenocarcinoma 2 . Other malignancy within past 3 year except follow : adequately treat cervical vulvar carcinoma situ , treat basal cell squamous carcinoma skin , superficial bladder tumor ( Ta , Tis &amp; T1 ) , ductal carcinoma situ ( DCIS ) breast low grade prostate cancer . Any cancer curatively treat &gt; 3 year prior entry clinical evidence recurrence permit . 3 . Hypersensitivity 5FU , oxaliplatin ( platinum agent ) , irinotecan ( excipients ) . 4 . Participation investigational drug study within 4 week precede start study treatment . Patients permit participate another investigational drug study treat protocol . 5 . Inability receive port PICC line . 6 . History suspect Gilbert 's Disease ( test require presence suspect ) . 7 . Baseline peripheral neuropathy/paresthesia grade ≥ 1 . 8 . Active hepatitis B , unless patient antiviral agent least 2 month ( baseline testing require ) . 9 . Active clinically serious infection ( &gt; grade 2 ) . 10 . Major surgery significant traumatic injury within 8 week first study drug . A core pancreatic liver biopsy preclude patient study . 11 . Unable unwilling discontinue use ketoconazole St John 's wort . Use phenytoin , carbamazepine , phenobarbital , rifampin rifabutin discourage , contraindicate . If patient require phenytoin , carbamazepine phenobarbital monitor drug level suggest study . 12 . Pregnant lactating woman . 13 . Psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pancreatic</keyword>
	<keyword>Cancer</keyword>
	<keyword>Resectable</keyword>
</DOC>